Conrad Tseng
Endocrinology, Diabetes & Metabolism · Beverly Hills, CANPI 1013924455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 848 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,806 and has fallen 99.1% since, to $34 in 2025.
Across 848 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- AbbVie$1K
- Insulet Corporation$1K
- Amgen$917
- plus $9K from 48 others
What the payments were for
- Food & beverage$17,06299%
- Education$330%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$17,155 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $89,349 |
| JardianceEmpagliflozin | 78 | $82,957 |
| JanuviaSitagliptin Phosphate | 62 | $63,259 |
| TrulicityDulaglutide | 33 | $38,717 |
| FarxigaDapagliflozin Propanediol | 28 | $28,685 |
| Humalog Kwikpen U-100Insulin Lispro | 61 | $18,422 |
| TradjentaLinagliptin | 13 | $13,463 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $10,554 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,865 |
| Novolog FlexpenInsulin Aspart | 38 | $8,478 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,531 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $6,370 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 39 | $6,254 |
| Nateglinide | 76 | $5,553 |
| HumalogInsulin Lispro | 28 | $5,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,381 | $96,42091 claims |
| Novo NordiskOzempic | $2,334 | $89,34966 claims |
| MerckJanuvia | $477 | $63,25962 claims |
| Lilly USA, LLCTrulicity, Humalog | $1,652 | $43,95561 claims |
| AstraZenecaFarxiga | $659 | $28,68528 claims |
| AbbVieSynthroid | $1,153 | $3,96158 claims |
| Sanofi-aventis U.S. LLCLantus | $826 | $2,08516 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $36 | $1,887174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Beverly Hills
- Anne PetersBeverly Hills$121K
- Reza NazemiBeverly Hills$97K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.